# Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer

> **NCT03241810** · PHASE2 · TERMINATED · sponsor: **Elevation Oncology** · enrollment: 22 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Seribantumab
- **DRUG:** Fulvestrant
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03241810
- **Lead sponsor:** Elevation Oncology
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-08-15
- **Primary completion:** 2018-11-30
- **Final completion:** 2018-11-30
- **Target enrollment:** 22 (ACTUAL)
- **Why stopped:** Merrimack Inc. terminated the trial early due to business decision
- **Last updated:** 2020-09-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03241810

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03241810, "Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03241810. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*